A Randomized, Multicentre, Open-Label Controlled Phase II Trial of Foxy-5 as Neo-Adjuvant Therapy in Subjects with Wnt-5a Low Colon Cancer
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2019
Price : $35 *
At a glance
- Drugs Foxy 5 (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colon cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NeoFox
- Sponsors WntResearch
- 30 Aug 2019 According to a WntResearch media release, company and The Sage Group have initiated a collaboration to accelerate the process of identifying and engaging potential partners prior to readout of this study.
- 26 Apr 2019 Last checked against ClinicalTrials.gov
- 23 Jan 2019 Status changed from planning to recruiting.